ClinicalTrials.gg
RecruitingNCT07281534REPEATCPETechoUpdated Dec 15, 2025

Test-Retest Reliability of Cardiopulmonary Exercise Testing With Echocardiography

An interventional study of CPETecho in Dyspnea; Cardiac, sponsored by Ziekenhuis Oost-Limburg. Recruiting at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Ziekenhuis Oost-Limburg · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Dyspnea with a site in Belgium — 3 open to participants now, 3 under way, none of them phase 3. Dyspnea · Belgium.

Planned enrollment
10th of 13
30 · median 120
Started
2025
with 1 other
No phase
5 of 19
2 open now
Registered
18th of 19
by date

Among the 19 studies in Dyspnea with a site in Belgium, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 18th registered.

Dyspnea

895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.

Browse Dyspnea studies →

Open to participants now

3 of the 19 studies in Dyspnea with a site in Belgium are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Dyspnea with a site in Belgium, or all of them as a file.
02

Study summary

CPETecho is progressively employed in diagnostic settings for pathophysiological detection, offering comprehensive assessment of both pulmonary and cardiac functions. This technique evolves from its invasive counterpart, where a diagnostic catheter is employed for hemodynamic monitoring, by substituting the invasive component with non-invasive echocardiography. Nevertheless, data on the test-retest reliability of CPETecho remain sparse, a factor critical in differentiating between measurement effects and actual therapeutic impacts.

03

Conditions studied

  • Dyspnea; Cardiac

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of performing a maximal exercise test.
  • Provide signed and dated .

Exclusion criteria

Exclusion Criteria:

- Unstable symptoms, whereby therapy cannot be delayed for a week.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Single arm

    Repeat CPET echo with a one-week interval

    Diagnostic Test: CPETecho

Interventions

  • Diagnostic testCPETecho

    repeat CPETecho with a one-week interval

06

What researchers measure

Primary outcomes

  1. Correlation coefficient (ICC)

    Analysing the Test-Retest Reliability of Cardiopulmonary Exercise Testing with Echocardiography

    Time frame: Up to 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2026, 4 months after the start.

Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 4 months is below that.

Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Dec 15, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Mar 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07281534
Lead sponsor
Ziekenhuis Oost-Limburg
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Nov 1, 2025
Primary completion
Mar 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Dec 15, 2025

Study contacts

Philippe Bertrand, MD, PhD
Contact
philippe.bertrand@zol.be
0032471626094
Sebastiaan Dhont, MD
Contact
sebastiaan.dhont@zol.be
0032471626094

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion